Nigel P Murray

15PUBLICATIONS
17CO-AUTHORS
Predictive and prognostic markersAutoimmunityMedical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Medical microbiology not elsewhere classified
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Aug 27, 2026
Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.

|Sep 26, 2025
Intravascular Lymphoma Presenting as Multiple Endocrine Failure, Transforming Into the Hemophagocytic Variant, and Relapsing as a Thrombotic Microangiopathy.

Nigel P Murray, Cinthia Escobar, Enrique Ramos

|Oct 29, 2023
The Possible Role of Matrix Metalloprotienase-2 in the Relapse in Patients with Stage II Colon Cancer Treated by Curative Surgery.

Nigel P Murray, Ricardo Villalon, Socrates Aedo

|Jul 28, 2022
Increasing Immune Dysfunction is Associated with Increasing Matrix-Metalloproteinase-2 Expression and Predicts Biochemical Failure in Men with Bone Marrow Micro-Metastasis Positive Localized Prostate Cancer.

Nigel P Murray, Socrates Aedo, Cynthia Fuentealba

|Feb 28, 2022
Improvement in the Neutrophil-Lymphocyte Ratio after Combined Fluorouracil, Leucovorina and Oxaliplatino based (FOLFOX) Chemotherapy for Stage III Colon Cancer is Associated with Improved Minimal Residual Disease and Outcome.

Nigel P Murray, Ricardo Villalon, Dan Hartmann

|Sep 02, 2021
Improvement in immune dysfunction after FOLFOX chemotherapy for Stage III colon cancer is associated with improved minimal residual disease prognostic subtype and outcome.

Nigel P Murray, Ricardo Villalon, Dan Hartmann

Pageof 3

Frequent Collaborators

5 joint publications

Aníbal Salazar

5 joint publications

Eduardo Reyes

5 joint publications

Shenda Orrego

5 joint publications

Ricardo Villalon